CORRELATION OF HEPATITIS B AND HEPATITIS C INFECTED CASES WITH LIVER FUNCTION TEST IN SIR GANGA RAM HOSPITAL LAHORE, PAKISTAN
Article Sidebar
Main Article Content
Abstract
Hepatitis B and C virus (HBV, HCV) remains a global health burden, often leading to progressive liver damage including cirrhosis and hepatocellular carcinoma. Liver function tests (LFTs), including ALT, AST, ALP, bilirubin, and albumin, serve as non-invasive indicators of hepatic inflammation, hepatocellular injury, and synthetic dysfunction. The aim of this study was to determine the correlation of hepatitis B and C infection with abnormalities in liver function tests among patients at Sir Ganga Ram Hospital, Lahore, Pakistan. A cross-sectional study was conducted at the pathology and clinical biochemistry departments. A total of 323 HBV (161) and HCV (162) positive patients were included in the study. Venous blood samples were collected under aseptic conditions and analyzed for liver function parameters. Parameters levels were measured using automated chemistry analyzers Mindray BS-200 and ROCHE COBAS C311. Among 161 HBV-positive patients, ALT, AST and ALP was recorded as 45.2±18.3, 50.5±21.4 and 110.7±34.2 respectively. Among 162 HCV-positive patients, ALT, AST and ALP was recorded as 62.7±22.7, 79.8±24.3 and 129.6±39.1 respectively. HCV infection significantly alters liver enzyme more as compared to HBV. These findings support the importance of regular liver function monitoring to ensure timely diagnosis and management of hepatic complications.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Lim YS. Treatment decisions based on HBV DNA. J Viral Hepat. 2024;31 Suppl 2:36-42.
Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol. 2023;29(44):5907-18.
Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther. 2023;57(5):464-74.
Luo J, Liang X, Xin J, Li J, Li P, Zhou Q, et al. Predicting the Onset of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2023;21(3):681-93.
Ginès P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75(1):219-28.
Zhan J, Wang J, Zhang Z, Xue R, Jiang S, Liu J, et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase. Virulence. 2023;14(1):2268497.
Kim GA, Choi SW, Han S, Lim YS. Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B. Clin Mol Hepatol. 2024;30(4):793-806.
Liaw YF. Hepatitis B flare: the good, the bad and the ugly. Expert Rev Gastroenterol Hepatol. 2022;16(11-12):1043-51.
Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci. 2022;23(3).
Lim YS. Gray zone of hepatitis B virus infection. Saudi J Gastroenterol. 2024;30(2):76-82.
Li G, Zhang P, Zhu Y. Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literature. J Viral Hepat. 2023;30(2):90-100.
Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023;78(5):1558-68.
Wang P, Zhang L, He J, Zhang G, Ma Y, Lv W, et al. Accuracy of hepatitis B disease surveillance, Gannan prefecture, Gansu province, China; 2017. PLoS One. 2022;17(9):e0274798.
Arain MA, Laghari ZA, Samo AA, Memon SF, Shaikh SA, Warsi J. Prevalence and risk factors associated with Hepatitis B and Hepatitis C infection in Mirpurkhas, Sindh, Pakistan. Rawal Medical Journal. 2020;45(4):750
Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. WIREs mechanisms of disease. 2021 Jan;13(1):e1499.
Mehmood S, Raza H, Abid F, Saeed N, Rehman HM, Javed S, Khan MS. National prevalence rate of hepatitis B and C in Pakistan and its risk factors. Journal of Public Health. 2020;28(6):751-64.
pradat, Zaman F, Uzman MH, Shabbir T, Khan NU, Atta S, Shiraz S, Zahid MA, Munir A. Prevalence of Hepatitis C in Liver Cirrhosis Patients: HCV Prevalence in Cirrhosis Patients. Journal of Health and Rehabilitation Research. 2024 Sep 18;4(3):1-4.
Ahmad I, Jan H, Malik SM, Ali Q, Haq I, Hassan I, Ullah I, Raza A, Shaukat A, Khalid F, Rehmat N. Comparative Evaluation of ALT & AST Levels of Hepatitis B and C Infected Pregnant Women in Lahore, Pakistan. Annals of RSCB. 2021;25(6):19829-37
Saadatifar, H., Mard-Soltani, M., Niayeshfar, A., Shakerian, N., Pouriamehr, S., Alinezhad Dezfuli, D., Khalili, S., Saadatifar, S. and Mashhadi, S.M., 2024. Correlation between plasma biochemical parameters and cardio-hepatic iron deposition in thalassemia major patients. Scandinavian Journal of Clinical and Laboratory Investigation, 84(4), pp.245-251.
KHALID S, SHAH N, ZAIDI YA, HASAN MS, JAHANGIR S, REHMAN S. Cardiomyopathy in Cirrhotic Patients and Its Relationship with the Severity of Cirrhosis. Age (years). 2021; 51:9-8.